Ramin Hassankhani
As a SALHN Ryan Hodges Research Fellow at BHI Clinical Pharmacology research group, I coordinate the ADAPT program (Accurate Dosing of Anti-cancer Patient-centred Therapies). My PhD in Medical & Health Sciences from UniSA focused on anti-cancer drug discovery and development, particularly Cyclin-Dependent Kinase (CDK) Inhibitors, with both preclinical and clinical applications. Currently, I'm expanding Therapeutic Drug Monitoring (TDM) research for targeted therapies aiming to advance precision medicine for cancer patients in South Australia.
Abstracts this author is presenting:
